We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+16.07%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$758M
AUM Growth
+$50.6M
Cap. Flow
+$36.9M
Cap. Flow %
4.87%
Top 10 Hldgs %
65.47%
Holding
63
New
21
Increased
16
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$42.2M
2
CBIO
Crescent Biopharma
CBIO
+$15M
3
ACOG
Alpha Cognition
ACOG
+$12.4M
4
SLGL icon
Sol-Gel Technologies
SLGL
+$9.61M
5
URGN icon
UroGen Pharma
URGN
+$5.82M

Top Sells

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$37.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$14M
3
CDXS icon
Codexis
CDXS
+$12.2M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$11.3M
5
LRMR icon
Larimar Therapeutics
LRMR
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
26
Karyopharm Therapeutics
KPTI
$42.4M
$6.84M 0.9%
+930,000
New +$5.69M
JBIO
27
Jade Biosciences
JBIO
$1.33B
$6.6M 0.87%
+427,608
New +$5.02M
URGN icon
28
UroGen Pharma
URGN
$2.13B
$6.29M 0.83%
+268,423
New +$5.82M
ALMS
29
Alumis Inc
ALMS
$2.9B
$5.22M 0.69%
535,000
-130,000
-20% -$908K
CATX icon
30
Perspective Therapeutics
CATX
$355M
$4.99M 0.66%
+1,184,500
New +$3.38M
VYGR icon
31
Voyager Therapeutics
VYGR
$218M
$4.7M 0.62%
+1,196,904
New +$5.29M
RLMD icon
32
Relmada Therapeutics
RLMD
$462M
$4.52M 0.6%
+935,000
New +$3.13M
TECX
33
Tectonic Therapeutic
TECX
$696M
$4.48M 0.59%
+214,747
New +$3.99M
PLX icon
34
Protalix BioTherapeutics
PLX
$205M
$4.46M 0.59%
2,478,176
-102,380
-4% -$209K
TRVI icon
35
Trevi Therapeutics
TRVI
$2.39B
$4.32M 0.57%
345,100
-44,900
-12% -$519K
FBIO icon
36
Fortress Biotech
FBIO
$92.4M
$3.99M 0.53%
+1,090,000
New +$3.11M
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$424M
$3.35M 0.44%
+955,000
New +$3.27M
MGTX icon
38
MeiraGTx Holdings
MGTX
$1.33B
$3.11M 0.41%
+390,844
New +$3.25M
RIGL icon
39
Rigel Pharmaceuticals
RIGL
$868M
$3M 0.4%
70,000
+32,213
+85% +$1.21M
ZYME icon
40
Zymeworks
ZYME
$2.02B
$2.87M 0.38%
108,929
+8,929
+9% +$195K
ASRT
41
DELISTED
Assertio
ASRT
$2.58M 0.34%
+285,000
New +$3.33M
VTYX
42
DELISTED
Ventyx Biosciences
VTYX
$2.27M 0.3%
+251,932
New +$1.88M
IRD
43
Opus Genetics
IRD
$307M
$2.25M 0.3%
1,120,000
+20,000
+2% +$40.6K
STRO icon
44
Sutro Biopharma
STRO
$339M
$2.21M 0.29%
+190,671
New +$1.81M
CABA icon
45
Cabaletta Bio
CABA
$529M
$1.97M 0.26%
900,000
+91,118
+11% +$226K
ZNTL icon
46
Zentalis Pharmaceuticals
ZNTL
$360M
$1.89M 0.25%
1,400,906
+1,084,356
+343% +$1.58M
GBIO
47
DELISTED
Generation Bio
GBIO
$1.76M 0.23%
+310,000
New +$1.75M
BBIO icon
48
BridgeBio Pharma
BBIO
$15B
$1.4M 0.18%
+18,319
New +$1.2M
ENTA icon
49
Enanta Pharmaceuticals
ENTA
$396M
$1.18M 0.16%
+75,000
New +$953K
QTTB icon
50
Q32 Bio
QTTB
$447M
$708K 0.09%
+213,363
New +$603K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2025 Portfolio in Review

As of Q4 2025, Opaleye Management held 63 positions worth $758M, up 7.1% from $707M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $36.9M of net new capital in Q4 2025, opening 21 new positions and adding to 16 existing holdings. Its largest new stake was Crescent Biopharma: 1,178,300 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Rhythm Pharmaceuticals, an estimated $14M trimmed.

  • Opaleye Management's largest Q4 2025 buy was Crescent Biopharma: 1,178,300 shares worth $14M.
  • Opaleye Management added most to Rezolute in Q4 2025, an estimated $42.2M increase.
  • Opaleye Management's biggest Q4 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $14M.
  • Opaleye Management fully exited Immunome in Q4 2025, selling an estimated $37.3M.
  • Opaleye Management's ten largest holdings make up 65% of its $758M portfolio in Q4 2025.
  • Opaleye Management opened 21 new positions and closed 9 in Q4 2025.
  • Opaleye Management's portfolio value rose 7.1% quarter-over-quarter to $758M.

Based on Opaleye Management's 13F filing for Q4 2025, filed 17 Feb 2026.